(Albany, United States) As per DelveInsight’s assessment, globally, the Oropharyngeal Cancer Pipeline constitutes 10+ key companies continuously working towards developing 10+ Oropharyngeal Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Oropharyngeal Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oropharyngeal Cancer NDA approvals (if any), and product development activities comprising the technology, Oropharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Oropharyngeal Cancer Pipeline treatment landscape of the report, click here @ Oropharyngeal Cancer Pipeline Outlook
Key Takeaways from the Oropharyngeal Cancer Pipeline Report
- DelveInsight’s Oropharyngeal Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
- The leading companies are working in the Oropharyngeal Cancer market include AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others.
- Promising Oropharyngeal Cancer Pipeline Therapies in the various stages of development include ISA101b, Cisplatin, Cemiplimab, Durvalumab, HB-201 IV, Nivolumab Injection, GC4419, APG-157, Nivolumab, Carboplatin, Paclitaxel, and others.
- On April 2023, ISA Pharmaceuticals announced a study of phase 2 clinical trials for ISA101b. This study will assess the ability of ISA101b plus cemiplimab to improve Overall Response Rate in subjects who have progressed on prior anti-PD-1 therapy.
- On April 2023, Fox Chase Cancer Center announced a study of phase 2 clinical trials for Cisplatin. This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
Oropharyngeal Cancer Overview
Oropharyngeal Cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat.
For further information, refer to the detailed Oropharyngeal Cancer Unmet Needs, click here for Oropharyngeal Cancer Ongoing Clinical Trial Analysis
Oropharyngeal Cancer Emerging Drugs Profile
- Cisplatin: AstraZeneca
Cisplatin works by stopping the cancer cells from multiplying. It does this by binding together the strands of the cells’ genetic material, DNA. Cisplatin binds to the N7 reactive center on purine residues and as such can cause deoxyribonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting in apoptotic cell death. The drug is being evaluated in Phase III clinical trials in combination with Durvalumab for the treatment of patients with Oropharyngeal cancer.
- ISA101B: ISA Pharmaceuticals
ISA101 consists of 12 synthetic long peptides (25 to 35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. The drug is currently in Phase II stage of development for the treatment of patients with Oropharyngeal cancer.
Oropharyngeal Cancer Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Oropharyngeal Cancer. The Oropharyngeal Cancer companies which have their Oropharyngeal Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.
Request a sample and discover the recent advances in Oropharyngeal Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Oropharyngeal Cancer Segmentation
Oropharyngeal Cancer Drugs and Companies
- ISA101b: ISA Pharmaceuticals
- Cisplatin: Cardinal Health
- Cemiplimab: Regeneron Pharmaceuticals
Oropharyngeal Cancer Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Oropharyngeal Cancer Therapeutics Market include-
AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others.
Dive deep into rich insights for drugs for Oropharyngeal Cancer Pipeline, click here @ Oropharyngeal Cancer Unmet Needs and Analyst Views
Scope of the Oropharyngeal Cancer Pipeline Report
- Coverage- Global
- Companies- AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others.
- Therapies- ISA101b, Cisplatin, Cemiplimab, Durvalumab, HB-201 IV, Nivolumab Injection, GC4419, APG-157, Nivolumab, Carboplatin, Paclitaxel, and others.
- Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Oropharyngeal Cancer Merger and acquisitions, Licensing Activities
Table of content
- Introduction
- Executive Summary
- Oropharyngeal Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Oropharyngeal Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Oropharyngeal Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Cisplatin: AstraZeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ISA101B: ISA Pharmaceuticals
- Drug profiles in the detailed report…..
- Early stage products (Phase I/II)
- Genakumab: GeneScience Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Oropharyngeal Cancer Key Companies
- Oropharyngeal Cancer Key Products
- Oropharyngeal Cancer- Unmet Needs
- Oropharyngeal Cancer- Market Drivers and Barriers
- Oropharyngeal Cancer- Future Perspectives and Conclusion
- Oropharyngeal Cancer Analyst Views
- Oropharyngeal Cancer Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services